Savvy Psychopharmacology

Therapeutic drug monitoring of antipsychotics

Author and Disclosure Information

 

References

Clozapine levels may be reported by measuring the metabolite norclozapine, which is not correlated with efficacy, or as a total level (combination of clozapine and norclozapine). While norclozapine is not associated with efficacy, the ratio of clozapine to norclozapine may indicate adherence to the medication, or any enzymatic modulation (genetic or drug–drug interaction) that may increase or decrease total exposure. A ratio of 1.5 to 2.0 (clozapine to norclozapine) is optimal; a ratio <0.5 may indicate nonadherence; and a ratio >2.0 may indicate inhibited drug clearance. A 12-hour serum clozapine level of ≥350 ng/mL is more likely to predict treatment response.7

CASE CONTINUED

Mr. Q is carefully tapered from haloperidol while initiating clozapine at 25 mg/d. As he is titrated on clozapine, Mr. Q’s serum levels are periodically checked and compared with expected levels and levels associated with efficacy. Eventually, Mr. Q is titrated to a clozapine dose of 400 mg/d at bedtime.

While receiving clozapine for 4 weeks, Mr. Q’s psychotic symptoms resolve, and he is scheduled for follow-up in the outpatient clozapine clinic.

Related Resources

  • De Leon J. A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry. 2018; 51(1-02):63-68.
  • Meyer JM. Is monitoring of plasma antipsychotic levels useful? Current Psychiatry. 2015;14(11):16,19-20.

Drug Brand Names

Aripiprazole • Abilify
Clozapine • Clozaril
Fluphenazine • Prolixin
Haloperidol • Haldol
Lithium • Eskalith, Lithobid
Lurasidone • Latuda
Olanzapine • Zyprexa
Perphenazine • Trilafon
Quetiapine • Seroquel
Risperidone • Risperdal
Valproic acid • Depakene, Depakote
Ziprasidone • Geodon

Pages

Recommended Reading

Prosody recognition associated with functioning in first-episode schizophrenia
MDedge Psychiatry
The Great Pretender
MDedge Psychiatry
Pimavanserin reduced dementia-related psychotic symptoms without affecting cognition
MDedge Psychiatry
Sequential intercept model is really a ‘no-intercept model’
MDedge Psychiatry
Schizophrenia, bipolar disorder associated with increased risk of secondary TD
MDedge Psychiatry
FDA approves Caplyta to treat schizophrenia in adults
MDedge Psychiatry
Antipsychotics, dopamine, and pain
MDedge Psychiatry
Half of SLE patients have incident neuropsychiatric events
MDedge Psychiatry
FDA strengthens warning regarding clozapine, serious bowel complication risk
MDedge Psychiatry
Understanding postpartum psychosis: From course to treatment
MDedge Psychiatry